跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 23,516 条关于
“Indolent Systemic Mastocytosis”
全部
23,516
临床试验
18,865
药物
218
机构
232
资讯
4,201
去年
Avapritinib Shows Durable Long-Term Response in Indolent Systemic Mastocytosis as Pipeline Expands
3个月前
Ayvakit (Avapritinib) Emerges as Targeted Therapy for Indolent Systemic Mastocytosis, Addressing Root Cause of Rare Mast Cell Disease
9个月前
Blueprint Medicines Reports Long-Term Efficacy Data for AYVAKIT in Systemic Mastocytosis at ASH 2025
去年
Sanofi Acquires Blueprint Medicines for $9.1 Billion to Strengthen Rare Disease and Immunology Portfolio
去年
Avapritinib Shows Promising Improvements in Bone Density for Advanced Systemic Mastocytosis Patients
去年
Avapritinib Demonstrates Long-Term Benefits in Advanced Systemic Mastocytosis
4个月前
Ayvakit (Avapritinib): High Response Rates in Rare Cancers and Mastocytosis, With Critical Safety Monitoring Requirements
去年
Bezuclastinib Shows Strong Symptom and Biomarker Improvement in Non-Advanced Systemic Mastocytosis
去年
Blueprint Medicines Announces Positive BLU-808 Phase 1 Data and 2025 Growth Strategy
去年
Bezuclastinib Shows Promise in Advanced Systemic Mastocytosis Treatment
第 1 页，共 421 页
上一页
下一页
